Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
TXG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.80 - $48.42
Previous CloseN/A
Volume385.49K
Average Volume (3M)2.63M
Market Cap
$1.48B
Enterprise Value$2.41B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Apr 30, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding108,245,010
10 Day Avg. Volume3,836,068
30 Day Avg. Volume2,628,106
Standard Deviation0.17
R-Squared0.34
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.42
Price to Cash Flow (P/CF)-54.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.82
Enterprise Value/Ebitda-18.42
Forecast
1Y Price Target
$16.82Price Target Upside45.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Biopharma Penetration10X Genomics is confident in increasing biopharma penetration, with expectations for its biopharma revenue mix to approach 50% over time.
EarningsRevenues beat expectations with a 9% increase, indicating strong performance.
Growth PotentialChromium reactions and spatial revenues are expected to grow in double digits, highlighting potential growth areas.
Bears Say
CompetitionThe ongoing reorganization of TXG's sales force coincides with the introduction of lower-priced competition, adding further challenges.
NIH Funding ImpactTXG's business has significant exposure to the academic end-market, especially in the U.S., which is impacted by the recently implemented NIH indirect costs cap.
Sales ForecastThe FY25 guidance for sales was below Street estimates, indicating potential challenges ahead.
---
Ownership Overview
2.09% Insiders
27.79% Mutual Funds
38.80% Other Institutional Investors
6.73% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TXG FAQ
What was 10x Genomics Inc’s price range in the past 12 months?
10x Genomics Inc lowest stock price was $10.80 and its highest was $48.42 in the past 12 months.
What is 10x Genomics Inc’s market cap?
10x Genomics Inc’s market cap is $1.48B.
When is 10x Genomics Inc’s upcoming earnings report date?
10x Genomics Inc’s upcoming earnings report date is Apr 30, 2025 which is in 67 days.
How were 10x Genomics Inc’s earnings last quarter?
10x Genomics Inc released its earnings results on Feb 12, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.299 by -$0.101.
Is 10x Genomics Inc overvalued?
According to Wall Street analysts 10x Genomics Inc’s price is currently Undervalued.
Does 10x Genomics Inc pay dividends?
10x Genomics Inc does not currently pay dividends.
What is 10x Genomics Inc’s EPS estimate?
10x Genomics Inc’s EPS estimate is -0.46.
How many shares outstanding does 10x Genomics Inc have?
10x Genomics Inc has 108,245,010 shares outstanding.
What happened to 10x Genomics Inc’s price movement after its last earnings report?
10x Genomics Inc reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.299. Following the earnings report the stock price went down -0.5%.
Which hedge fund is a major shareholder of 10x Genomics Inc?
Currently, no hedge funds are holding shares in TXG
---
10x Genomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.82 (45.50% Upside)
$16.82 (45.50% Upside)
Blogger Sentiment
Bearish
TXG Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $171.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.64%
12-Months-Change
Fundamentals
Return on Equity
-25.17%
Trailing 12-Months
Asset Growth
-4.82%
Trailing 12-Months
Company Description
10x Genomics Inc
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.
---
TXG Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While the company experienced significant product innovation and customer adoption, challenges such as revenue decline, market uncertainties, and reduced funding from key stakeholders like NIH have created a cautious outlook. The highlights are balanced by substantial lowlights, leading to an overall neutral sentiment.Read More>---
TXG Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China
---
TXG Stock 12 Month Forecast
Average Price Target
$16.82
▲(45.50% Upside)
Technical Analysis
Illumina
―
Pacific Biosciences
―
Crispr Therapeutics AG
―
Guardant Health
―
Twist Bioscience
―
Best Analysts Covering TXG
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
+5.37%
reiterated a buy rating 9 days ago
Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of +5.37% per trade.
---